Morgan Stanley analyst Matthew Harrison lowered the firm’s price target on Biogen to $349 from $351 and keeps an Overweight rating on the shares. The firm issued its biotechnology Q1 sector preview, stating that broadly for the group it does not "expect many surprises" given recently issued guidance. The firm sees investor focus being mainly on Q2 catalysts in the space.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen price target lowered to $307 from $310 at Barclays
- Truist biotechnology analyst to hold an analyst/industry conference call
- Drugmakers call for abortion pill ruling reversal, Reuters reports
- FDA AdCom to convene on June 9th to discuss Biogen/Eisai’s LEQEMBI in AD
- JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data